| |
No. of isolates
|
Unadjusted
|
Adjusted by age, sex and areas
|
|---|
|
Total
|
Clustered (%)
|
OR*
|
95 % CI*
|
OR*
|
95 % CI*
|
|---|
|
Socio and clinical factors
|
|
Sex
|
|
Female
|
33
|
7 (21.2)
|
1
| |
1
| |
|
Male
|
101
|
26 (25.7)
|
1.29
|
0.469–3.931
|
1.20
|
0.435–4.041
|
|
Treatment episode
|
|
=2
|
76
|
13 (17.1)
|
1
| |
1
| |
|
≥3
|
58
|
20 (34.5)
|
2.55
|
1.060–6.238**
|
2.41
|
1.012–6.543**
|
|
Sputum smear
|
|
Negative
|
9
|
2 (22.2)
|
1
| |
1
| |
|
Positive
|
125
|
31 (24.8)
|
1.15
|
0.205–11.94
|
1.12
|
0.201–12.02
|
|
Drug resistance and genetic mutation:
|
|
Other DR
|
60
|
9 (15.0)
|
1
| |
1
| |
|
MDR
|
70
|
24 (34.3)
|
2.45
|
1.008–6.363**
|
2.43
|
1.007–6.471**
|
|
preXDR/XDR
|
25
|
6 (24.0)
|
1.79
|
0.456–6.520
|
1.81
|
0.451–6.522
|
|
Drug resistant isolates with mutation in:
|
|
WT
|
38
|
7 (18.4)
|
1
| |
1
| |
|
katG
|
59
|
12 (20.3)
|
1.33
|
0.421–4.470
|
1.28
|
0.419–4.451
|
|
rpoB
|
55
|
21 (38.2)
|
2.74
|
0.943–8.622
|
2.64
|
0.873–8.953
|
|
pncA
|
39
|
8 (20.5)
|
1.14
|
0.317–4.197
|
1.15
|
0.313–4.221
|
|
gyrA
|
11
|
3 (27.3)
|
1.66
|
0.224–9.531
|
1.53
|
0.214–9.524
|
|
rrs
|
7
|
1 (14.3)
|
0.74
|
0.014–7.907
|
0.71
|
0.010–8.123
|
|
eis
|
4
|
0 (0)
|
-
| |
-
| |
- MDR multidrug resistance, XDR extensively drug resistance
- *OR and 95 % CI were calculated in the binary logistic regression model
- **p < 0.05
